Senhwa Biosciences Inc (生華科) aims to raise NT$1.5 billion (US$50.57 million) by issuing 15 million new common shares in the third quarter of this year to fund the research of new drugs, including the experimental drug Silmitasertib for the treatment of COVID-19, the company said on Monday.
That would be the firm’s largest fundraising effort after it raised more than NT$1.4 billion from an initial public offering on the Taipei Exchange (TPEX) in April 2017, chief financial officer Sarah Chang (張小萍) told the Taipei Times by telephone.
The price of the new shares would depend on the firm’s average share price over the five days before the secondary offering, Chang said. Companies usually offer discounts of up to 30 percent, she said.
As Senhwa Biosciences shares have stayed above NT$100 in the past few months, the company expects to raise at least NT$1.5 billion from the issuance of 15 million new shares, Chang said.
The fresh funds would fuel the company’s research and development of Silmitasertib, or CX-4945, which is a small-molecule drug for cancers, such as bile duct cancer, but has shown potential to combat the novel coronavirus with its capability to curb replication of the ribonucleic acid virus.
The company plans to test the drug on mice to evaluate its efficacy in cooperation with the US National Institutes of Health (NIH) next month, Senhwa Biosciences chief executive officer Soong Tai-sen (宋台生) said by telephone yesterday.
The preparation of the animal tests would take some time, as the mice first need to be genetically engineered to have a human version of a protein known as the angiotensin-converting enzyme 2 receptor, which the coronavirus uses as its point of entry, Soong said.
He expects the animal tests to be completed by the end of next month.
As conducting human tests with the experimental drug would be expensive, with an average cost of US$80,000 per subject, Senhwa Biosciences plans to apply to foreign agencies, such as the US Biomedical Advanced Research and Development Authority, for sponsorship, Soong said.
“Although the development of vaccines against COVID-19 is eye-catching, I think drugs will be the real solution for the pandemic, as COVID-19 antibodies might fade in less than two months, according to recent studies,” Soong said.
Senhwa Biosciences shares advanced 9.96 percent to NT$139.5 in Taipei trading yesterday, after an international team led by researchers at the University of California, San Francisco, identified Silmitasertib as one of the several drugs that could disrupt the viral takeover of cells.
The company’s shares have risen 120 percent from NT$63.5 in March, when the company began focusing on exploiting the experimental drug to treat COVID-19.
BYPASSING CHINA TARIFFS: In the first five months of this year, Foxconn sent US$4.4bn of iPhones to the US from India, compared with US$3.7bn in the whole of last year Nearly all the iPhones exported by Foxconn Technology Group (富士康科技集團) from India went to the US between March and last month, customs data showed, far above last year’s average of 50 percent and a clear sign of Apple Inc’s efforts to bypass high US tariffs imposed on China. The numbers, being reported by Reuters for the first time, show that Apple has realigned its India exports to almost exclusively serve the US market, when previously the devices were more widely distributed to nations including the Netherlands and the Czech Republic. During March to last month, Foxconn, known as Hon Hai Precision Industry
Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) and the University of Tokyo (UTokyo) yesterday announced the launch of the TSMC-UTokyo Lab to promote advanced semiconductor research, education and talent development. The lab is TSMC’s first laboratory collaboration with a university outside Taiwan, the company said in a statement. The lab would leverage “the extensive knowledge, experience, and creativity” of both institutions, the company said. It is located in the Asano Section of UTokyo’s Hongo, Tokyo, campus and would be managed by UTokyo faculty, guided by directors from UTokyo and TSMC, the company said. TSMC began working with UTokyo in 2019, resulting in 21 research projects,
Ashton Hall’s morning routine involves dunking his head in iced Saratoga Spring Water. For the company that sells the bottled water — Hall’s brand of choice for drinking, brushing his teeth and submerging himself — that is fantastic news. “We’re so thankful to this incredible fitness influencer called Ashton Hall,” Saratoga owner Primo Brands Corp’s CEO Robbert Rietbroek said on an earnings call after Hall’s morning routine video went viral. “He really helped put our brand on the map.” Primo Brands, which was not affiliated with Hall when he made his video, is among the increasing number of companies benefiting from influencer
Quanta Computer Inc (廣達) chairman Barry Lam (林百里) yesterday expressed a downbeat view about the prospects of humanoid robots, given high manufacturing costs and a lack of target customers. Despite rising demand and high expectations for humanoid robots, high research-and-development costs and uncertain profitability remain major concerns, Lam told reporters following the company’s annual shareholders’ meeting in Taoyuan. “Since it seems a bit unworthy to use such high-cost robots to do household chores, I believe robots designed for specific purposes would be more valuable and present a better business opportunity,” Lam said Instead of investing in humanoid robots, Quanta has opted to invest
RSS